Wels WS - Search Results

1

A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.

Biburger M, Weth R, Wels WS. Biburger M, et al. Among authors: wels ws. J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22. J Mol Biol. 2005. PMID: 15713482

2

Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.

Gerstmayer B, Altenschmidt U, Hoffmann M, Wels W. Gerstmayer B, et al. J Immunol. 1997 May 15;158(10):4584-90. J Immunol. 1997. PMID: 9144470

3

Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.

Gerstmayer B, Hoffmann M, Altenschmidt U, Wels W. Gerstmayer B, et al. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):156-8. doi: 10.1007/s002620050421. Cancer Immunol Immunother. 1997. PMID: 9435862 Free PMC article.

4

Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria.

Benhar I, Azriel R, Nahary L, Shaky S, Berdichevsky Y, Tamarkin A, Wels W. Benhar I, et al. J Mol Biol. 2000 Aug 25;301(4):893-904. doi: 10.1006/jmbi.2000.4021. J Mol Biol. 2000. PMID: 10966794

5

Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.

Rohrbach F, Gerstmayer B, Biburger M, Wels W. Rohrbach F, et al. Clin Cancer Res. 2000 Nov;6(11):4314-22. Clin Cancer Res. 2000. PMID: 11106249

6

Chimeric antigen receptors for the retargeting of cytotoxic effector cells.

Uherek C, Groner B, Wels W. Uherek C, et al. J Hematother Stem Cell Res. 2001 Aug;10(4):523-34. doi: 10.1089/15258160152509136. J Hematother Stem Cell Res. 2001. PMID: 11522235 Review.

7

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W. Uherek C, et al. Blood. 2002 Aug 15;100(4):1265-73. Blood. 2002. PMID: 12149207 Free article.

8

Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor.

Hyland S, Beerli RR, Barbas CF, Hynes NE, Wels W. Hyland S, et al. Oncogene. 2003 Mar 13;22(10):1557-67. doi: 10.1038/sj.onc.1206299. Oncogene. 2003. PMID: 12629519

9

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.

Wels W, Biburger M, Müller T, Dälken B, Giesübel U, Tonn T, Uherek C. Wels W, et al. Cancer Immunol Immunother. 2004 Mar;53(3):217-26. doi: 10.1007/s00262-003-0482-8. Epub 2003 Dec 24. Cancer Immunol Immunother. 2004. PMID: 14704833 Free PMC article. Review.

10

Therapeutic antibodies.

Groner B, Hartmann C, Wels W. Groner B, et al. Curr Mol Med. 2004 Aug;4(5):539-47. doi: 10.2174/1566524043360483. Curr Mol Med. 2004. PMID: 15267225 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters